



Fadlo R. Khuri, MD, *Deputy Director for Clinical and Translational Research, Blomeyer Professor of Hematology and Oncology, Professor of Hematology & Oncology, Otolaryngology, Medicine and Pharmacology, Chief Medical Officer of Emory Winship, and co-Director of the Institute's Cancer Drug Discovery, Development, and Delivery Program.*

Fadlo R. Khuri, M.D., serves the Emory Winship Cancer Institute as Deputy Director for Clinical and Translational Research, Blomeyer Professor of Hematology and Oncology, Professor of Hematology & Oncology, Otolaryngology, Medicine and Pharmacology, and Chief Medical Officer and co-Director of the Institute's Cancer Drug Discovery, Development, and Delivery Program.

Dr. Khuri earned his bachelor's degree from Yale University, in New Haven, CT, and his doctoral degree from Columbia University College of Physicians and Surgeons in New York, NY. He completed his residency in internal Medicine at the Boston City Hospital, Boston University School of Medicine. He then completed a fellowship in Hematology and Medical Oncology at the New England Medical Center, Tufts University School of Medicine. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of the American Association for Cancer Research, and the American Society of Clinical Oncology. He was on faculty at the University of Texas M.D. Anderson Cancer Center from 1995-2002 prior to joining Emory University.

Dr. Khuri's clinical interests include thoracic and head and neck oncology. His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in tobacco-related cancers.

Dr. Khuri is the recipient of numerous awards, including being listed among America's Top Doctors and the Marquis Who's Who in the World. He has been elected into the prestigious American Society for Clinical Investigation, and he is a Georgia Cancer Coalition Distinguished Clinical Scholar. Dr. Khuri serves on the editorial boards of 7 journals, including the Journal of Clinical Oncology, Clinical Cancer Research and Cancer, and has published over 100 peer reviewed articles in elite journals including Nature Medicine, Journal of the National Cancer Institute, Cancer Research and the Journal of Clinical Oncology. He has been the recipient of competitive, peer-reviewed federal grant support from the National Cancer Institute, Department of Defense, and American Cancer Society over the last decade.